• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Review: secretin is not effective for the treatment of children with autism spectrum disorders

QuestionQuestion

Does secretin improve the symptoms of autism spectrum disorders (ASDs) in children aged between 2 and 12 years old with ASDs?.

Outcomes

Principal outcomes included core symptoms of ASDs (including language and communication impairment, and cognitive and social skill deficits) and common comorbid symptoms (including sleep, anxiety, hyperactivity and challenging behaviour).

MethodsDesign

Systematic review.

Data sources

MEDLINE (via PubMed), PsycINFO, ERIC were searched from 2000 to May 2010. To identify additional studies, reference lists of all included articles were hand searched and clinical trials related to therapies for ASDs were reviewed.

Study selection and analysis

All studies of secretin with at least 30 participants younger than 12 years with ASDs, regardless of study design. Only studies published in and after the year 2000 were included, as this was after publication of the DSM-IV and the widespread use of gold-standard ASD assessment tools. Two reviewers independently extracted study data and assessed the…

Posted in: Meta-analyses - Systematic Reviews on 09/28/2011 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2025 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice